![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Preclinical Pharmacokinetics and Metabolism, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland (A.T., R.S.); and Division of Clinical Pharmacology and Toxicology, Department of Medicine, University Hospital, Zurich, Switzerland (B.S., S.H.)
The elimination process of the endothelin receptor antagonist bosentan (Tracleer) in humans is entirely dependent on metabolism mediated by two cytochrome P450 (P450) enzymes, i.e., CYP3A4 and CYP2C9. Most interactions with concomitantly administered drugs can be rationalized in terms of inhibition of these P450 enzymes. The increased bosentan concentrations observed in the presence of cyclosporin A, rifampicin, or sildenafil, however, are incompatible with this paradigm and prompted the search for alternative mechanisms governing these interactions. In the present article, we identify bosentan and its active plasma metabolite, Ro 48-5033 (4-(2-hydroxy-1,1-dimethyl-ethyl)-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-[2,2']bipyrimidinyl-4-yl]-benzenesulfonamide), as substrates of the human organic anion transporting polypeptides (OATP) OATP1B1 and OATP1B3. Bosentan uptake into Chinese hamster ovary cells expressing these OATP transporters was efficiently inhibited by cyclosporin A and rifampicin with IC50 values significantly below their effective plasma concentrations in humans. The phosphodiesterase-5 inhibitor sildenafil was also shown to interfere with OATP-mediated transport, however, at concentrations above those achieved in therapeutic use. Therefore, inhibition of bosentan hepatic uptake may represent an alternative/complementary mechanism to rationalize some of the pharmacokinetic interactions seen in therapeutic use. A similar picture has been drawn for drugs like pitavastatin and fexofenadine, drugs that are mainly excreted in unchanged form. Bosentan elimination, in contrast, is entirely dependent on metabolism. Therefore, the described interactions with rifampicin, cyclosporin A, and, to a lesser extent, sildenafil represent evidence that inhibition of hepatic uptake may become the rate-limiting step in the overall elimination process even for drugs whose elimination is entirely dependent on metabolism.
This article has been cited by other articles:
|
|
 |
|
  E. Gruenig, E. Michelakis, J.-L. Vachiery, C. D. Vizza, F. J. Meyer, M. Doelberg, D. Bach, J. Dingemanse, and N. Galie Acute Hemodynamic Effects of Single-Dose Sildenafil When Added to Established Bosentan Therapy in Patients With Pulmonary Arterial Hypertension: Results of the COMPASS-1 Study J. Clin. Pharmacol., November 1, 2009; 49(11): 1343 - 1352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Shitara, Y. Nagamatsu, S. Wada, Y. Sugiyama, and T. Horie Long-Lasting Inhibition of the Transporter-Mediated Hepatic Uptake of Sulfobromophthalein by Cyclosporin A in Rats Drug Metab. Dispos., June 1, 2009; 37(6): 1172 - 1178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Leuthold, B. Hagenbuch, N. Mohebbi, C. A. Wagner, P. J. Meier, and B. Stieger Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters Am J Physiol Cell Physiol, March 1, 2009; 296(3): C570 - C582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Woo, E. R. Gardner, X. Chen, S. B. Ockers, C. E. Baum, T. M. Sissung, D. K. Price, R. Frye, R. L. Piekarz, S. E. Bates, et al. Population Pharmacokinetics of Romidepsin in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma Clin. Cancer Res., February 15, 2009; 15(4): 1496 - 1503. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Bellingham, L. A. Coleman, C. L. Masters, J. Camakaris, and A. F. Hill Regulation of Prion Gene Expression by Transcription Factors SP1 and Metal Transcription Factor-1 J. Biol. Chem., January 9, 2009; 284(2): 1291 - 1301. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Poirier, T. Lave, R. Portmann, M.-E. Brun, F. Senner, M. Kansy, H.-P. Grimm, and C. Funk Design, Data Analysis, and Simulation of in Vitro Drug Transport Kinetic Experiments Using a Mechanistic in Vitro Model Drug Metab. Dispos., December 1, 2008; 36(12): 2434 - 2444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Shou, M. Hayashi, Y. Pan, Y. Xu, K. Morrissey, L. Xu, and G. L. Skiles Modeling, Prediction, and in Vitro in Vivo Correlation of CYP3A4 Induction Drug Metab. Dispos., November 1, 2008; 36(11): 2355 - 2370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Narushima, T. Takada, Y. Yamanashi, and H. Suzuki Niemann-Pick C1-Like 1 Mediates {alpha}-Tocopherol Transport Mol. Pharmacol., July 1, 2008; 74(1): 42 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Hariparsad, B. A. Carr, R. Evers, and X. Chu Comparison of Immortalized Fa2N-4 Cells and Human Hepatocytes as in Vitro Models for Cytochrome P450 Induction Drug Metab. Dispos., June 1, 2008; 36(6): 1046 - 1055. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Wrishko, J. Dingemanse, A. Yu, C. Darstein, D. L. Phillips, and M. I. Mitchell Pharmacokinetic Interaction Between Tadalafil and Bosentan in Healthy Male Subjects J. Clin. Pharmacol., May 1, 2008; 48(5): 610 - 618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Kalgutkar, B. Feng, H. T. Nguyen, K. S. Frederick, S. D. Campbell, H. L. Hatch, Y.-A. Bi, D. C. Kazolias, R. E. Davidson, R. J. Mireles, et al. Role of Transporters in the Disposition of the Selective Phosphodiesterase-4 Inhibitor (+)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic Acid in Rat and Human Drug Metab. Dispos., November 1, 2007; 35(11): 2111 - 2118. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
